The historical rank and industry rank for Maravai LifeSciences Holdings's Price-to-Free-Cash-Flow or its related term are showing as below:
MRVI'
s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.46 Med: 12.71 Max: 43.97
Current: 16.72
During the past 6 years, Maravai LifeSciences Holdings's highest Price-to-Free-Cash-Flow Ratio was 43.97. The lowest was 5.46. And the median was 12.71.
MRVI's Price-to-Free-Cash-Flow is ranked better than 71.03% of 214
companies
in the Biotechnology industry
Industry Median: 30.76
vs MRVI: 16.72
During the past 12 months, the average Free Cash Flow per Share Growth Rate of Maravai LifeSciences Holdings was -77.40% per year.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was -52.80% per year.
During the past 6 years, Maravai LifeSciences Holdings's highest 3-Year average Free Cash Flow per Share Growth Rate was 196.40% per year. The lowest was -52.80% per year. And the median was 71.80% per year.
Maravai LifeSciences Holdings Price-to-Free-Cash-Flow Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Maravai LifeSciences Holdings's Price-to-Free-Cash-Flow
For the Biotechnology subindustry, Maravai LifeSciences Holdings's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maravai LifeSciences Holdings's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Maravai LifeSciences Holdings's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Maravai LifeSciences Holdings's Price-to-Free-Cash-Flow falls into.
Maravai LifeSciences Holdings's Share Price of today is $7.70. Maravai LifeSciences Holdings's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.46.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Maravai LifeSciences Holdings Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Maravai LifeSciences Holdings's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Maravai LifeSciences Holdings (Maravai LifeSciences Holdings) Business Description
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. The company's segments are Nucleic acid production, Biologics safety testing, and Protein detection. It generates a majority of its revenue from the Nucleic Acid Production that focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MRVI has been successfully added to your 